PANCREATIC CARCINOMA METASTATIC

This adverse event was reported 2847 times

These drugs are most commonly taken by patients reporting PANCREATIC CARCINOMA METASTATIC:

# Drug Count
0 SITAGLIPTIN 531
1 PACLITAXEL 334
2 EXENATIDE 330
3 GEMCITABINE HYDROCHLORIDE 300
4 LIRAGLUTIDE 283
5 GEMCITABINE 270
6 METFORMIN 249
7 METFORMIN ER 500 MG 249
8 METFORMIN ER 750 MG 249
9 SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 212
See all common drugs associated with PANCREATIC CARCINOMA METASTATIC

PANCREATIC CARCINOMA METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 212 0.0098
1 ETHIODIZED OIL 12 0.0092
2 PIOGLITAZONE AND METFORMIN HYDROCHLORIDE 11 0.0087
3 SITAGLIPTIN 531 0.0073
4 EXENATIDE 330 0.0063
5 LIRAGLUTIDE 283 0.0057
6 GEMCITABINE HYDROCHLORIDE 300 0.0055
7 PANCRELIPASE 207 0.0052
8 ERLOTINIB HYDROCHLORIDE 44 0.0035
9 PACLITAXEL 334 0.0033
See all drugs enriched for association with PANCREATIC CARCINOMA METASTATIC

PANCREATIC CARCINOMA METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Cannabinoid [EPC] 18 0.0022
1 Tricyclic Antidepressant [EPC] 1 0.0021
2 Microtubule Inhibitor [EPC] 341 0.0021
3 Antihypoglycemic Agent [EPC] 7 0.0016
4 Lymphocyte Growth Factor [EPC] 2 0.0016
5 GLP-1 Receptor Agonist [EPC] 647 0.0014
6 Sulfonylurea [EPC] 158 0.0013
7 Glinide [EPC] 11 0.0012
8 gamma-Aminobutyric Acid A Receptor Agonist [EPC] 2 0.0012
9 Aldehyde Dehydrogenase Inhibitor [EPC] 1 0.0009
See all drug classes enriched for association with PANCREATIC CARCINOMA METASTATIC